Abcellera Financial Statements From 2010 to 2025
| ABCL Stock | USD 3.58 0.14 3.76% |
Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Biologics Company Shares Outstanding Analysis
Abcellera Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Abcellera Biologics Shares Outstanding | 299.34 M |
Most of Abcellera Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abcellera Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Abcellera Biologics has 299.34 M of shares currently outstending. This is 65.81% higher than that of the Biotechnology sector and 180.13% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 47.65% higher than that of the company.
Abcellera Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Abcellera Biologics's current stock value. Our valuation model uses many indicators to compare Abcellera Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abcellera Biologics competition to find correlations between indicators driving Abcellera Biologics's intrinsic value. More Info.Abcellera Biologics is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Abcellera Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Abcellera Biologics Financial Statements
Abcellera Biologics investors utilize fundamental indicators, such as revenue or net income, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Abcellera Biologics Correlation against competitors. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.